Cytovant is a biopharmaceutical company dedicated to developing novel and innovative cellular therapeutics in Asia
Our mission is to become Asia’s premier cell therapy company by rapidly discovering, developing, and commercializing new medicines tailored to Asian patients
TCR-T therapies utilize a patient’s own immune system to target tumor cells. In preparation for the therapy, a patient’s T cells are modified to express tumor-specific receptors that are then able to activate and mount an anti-tumor response. Through ex-vivo modification of a patient’s T cells, TCR-T therapy can overcome natural T cell tolerance toward cancer cells and tumor-induced immunosuppression. Unlike CAR-T therapy, TCR-T therapy is designed to recognize intracellular antigens in addition to extracellular antigens, which may increase the number of tumors that can be successfully targeted.
DC vaccines are patient-derived therapies in which a patient’s own DCs are loaded with tumor antigens to elicit immune responses against cancerous cells. Different tumor antigens can be loaded into DCs to treat various forms of cancer. As DC vaccines are designed to activate immune responses against tumor antigens over the course of vaccine administration, these therapies may be particularly suitable for cancer patients for whom prevention of disease relapse is the main treatment goal.
Cytovant’s medicine development technology platform is built on complementary immunotherapeutic approaches, including T cell receptor-engineered T cell (TCR-T) therapy and dendritic cell (DC) vaccine therapeutics: